Seagen Stock Soars On Pfizer Takeover Talks: What's Going On?

Seagen Inc SGEN shares are trading higher Monday following reports indicating pharmaceutical giant Pfizer Inc PFE is considering acquiring the biotech company.

What To Know: According to a Wall Street Journal report citing people familiar with the matter, Pfizer is in early stage talks to acquire Seagen. 

There is no guarantee that a deal will be reached and even if the companies come to an agreement, the deal is likely to face a potentially lengthy antitrust review.

Last year, WSJ reported that Seagen was in advanced talks to be acquired by Merck & Co Inc MRK, but an agreement never came to fruition. 

The report notes that Pfizer acquired both Global Blood Therapeutics Inc and Biohaven Pharmaceutical Holdings Co for more than $15 billion combined last year. Still the company has a sizable cash position of nearly $23 billion. Seagen had a market cap of $30.142 billion as of Friday's close, according to Benzinga Pro.

See Also: Pfizer In Early Talks To Buy Cancer-Focused Seagen: WSJ

SGEN Price Action: Seagen has a 52-week high of $183 and a 52-week low of $105.43. 

The stock was hovering near its 52-week highs, last up 12.8% at $182 Monday morning, according to Benzinga Pro.

Photo: courtesy of Pfizer.

Posted In: M&ANewsMoversWall Street Journalwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...